



**Oxford BioDynamics**  
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

**Issue of shares in lieu of salary,  
Director / PDMR shareholdings &  
Total voting rights**

**Oxford, UK - 24 December 2024** - Oxford BioDynamics, Plc (AIM: OBD, the Company) a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform, announces the issue of 2,742,657 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 1.1 per share (the "New Ordinary Shares") to its directors, PDMRs and certain other senior staff members to satisfy part of their salaries and fees, in line with the Company's ongoing strategy to preserve its cash resources as announced on 14 October 2024. The issue price is equal to the closing market price of the Company's Ordinary Shares on 23 December 2024, being the last practicable date prior to the issue of the New Ordinary Shares.

The New Ordinary Shares being issued have been allocated to the following directors and PDMRs:

Director / PDMR	Position	Number of New Ordinary Shares issued	Resultant shareholding in the Company	% of the issued share capital of the Company
Dr Alexandre Akoulitchev	Chief Scientific Officer	229,584	7,562,296	2.37%
Paul Stockdale	Chief Financial Officer	212,547	1,077,919	0.34%
Matthew Wakefield	Non-Executive Chairman	115,949	1,616,614	0.51%
Dr David Holbrook	Non-Executive Director	58,671	159,964	0.05%
Thomas Guiel	Chief Operating Officer	261,343	1,288,146	0.40%
Dr Ewan Hunter	Chief Data Officer	194,720	722,754	0.23%

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur at 8.00 a.m. on or around 31 December 2024. The New Ordinary Shares have been issued as fully paid and rank pari passu in all respects with the existing Ordinary Shares.

Following Admission, the Company's issued share capital will consist of 319,319,226 Ordinary Shares. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 319,319,226 and this figure may be used by Shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Further details of the PDMR dealings are included below. This information has been provided in accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

-Ends-

**For more information:**

**Oxford BioDynamics Plc**  
Matthew Wakefield, Non-Executive Chairman  
Paul Stockdale, CFO

+44 (0)1865 518910

**Shore Capital**  
(Nominated Adviser and Broker to OBD)  
Stephane Auton  
Lucy Bowden

+44 (0)20 7408 4090

.../ ...

**WG Partners**  
**(Joint Broker to OBD)**  
David Wilson / Claes Spång /  
Satheesh Nadarajah / Erland Sternby

+44 (0)20 3705 9330

**Oak Securities**  
**(Joint Broker to OBD)**  
Jerry Keen / Henry Clarke

+44 (0)20 3973 3678

**Vigo Consulting**  
**(Media / Analyst enquiries for OBD)**  
Rozi Morris

+44 (0)20 7390 0230  
obd@vigoconsulting.com

## Notes for Editors

### About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com), X (@OxBioDynamics) or [LinkedIn](#).

The notifications below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

### Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	1) Dr Alexandre Akoulitchev 2) Paul Stockdale 3) Matthew Wakefield 4) Dr David Holbrook 5) Thomas Guiel 6) Dr Ewan Hunter
2	Reason for the notification	
a)	Position/status	1) Chief Scientific Officer, Director 2) Chief Financial Officer, Director 3) Non-Executive Director 4) Non-Executive Director 5) Chief Operating Officer, PDMR 6) Chief Data Officer, PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Oxford Biodynamics plc
b)	LEI	2138005Y1TK25805U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of	

	transaction; (iii) each date; and (iv) each place where transactions have been conducted				
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares  ISIN: GB00BD5H8572			
b)	Nature of the transaction	Issue of New Ordinary Shares in lieu of salary			
c)	Price(s) and volume(s)		Price(s)	Volume(s)	
		1)	1.1p	229,584	
		2)	1.1p	212,547	
		3)	1.1p	115,949	
		4)	1.1p	58,671	
		5)	1.1p	261,343	
		6)	1.1p	194,720	
d)	Aggregated information  - Aggregated volume  - Price	N/A - single transactions			
e)	Date of the transaction	23 December 2024			
f)	Place of the transaction	London Stock Exchange (XLON)			

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDZMZZFFNGDZZ